Key terms
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OLMA news
Apr 12
11:55am ET
Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge
Apr 04
9:16pm ET
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
Apr 02
4:57am ET
Olema Oncology initiated with a Buy at Goldman Sachs
Mar 18
8:35am ET
5 Stocks that Analysts Love in March 2024
Mar 13
2:57am ET
3 Best Stocks to Buy Now, 3/13/2024, According to Top Analysts
Mar 12
9:45am ET
Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment
Mar 12
8:05am ET
Oppenheimer Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
Mar 12
8:05am ET
Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity
Mar 12
6:26am ET
Optimistic Outlook on Olema Pharmaceuticals: A Comprehensive Analysis of Palazestrant’s Clinical Advancements and Future Potential
Mar 11
8:25pm ET
Strong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals’ Palazestrant
Mar 11
4:06pm ET
Olema Oncology reports Q4 EPS (49c), consensus (48c)
Mar 06
2:05pm ET
Buy Rating for Olema Pharmaceuticals’ Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer Treatment
Mar 06
7:09am ET
Olema Oncology announces publication of data on palazestrant
Feb 29
11:27am ET
Olema Pharmaceuticals (NASDAQ:OLMA) Stock: Is There More Upside After a Remarkable Run in 2023?
Feb 22
7:54am ET
Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)
Feb 01
11:49pm ET
3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts
Feb 01
7:50am ET
Analysts Are Bullish on Top Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Siemens Healthineers AG (SEMHF)
Jan 31
4:24pm ET
Olema Oncology files to sell 13.21M shares of common stock for holders
Jan 30
5:04am ET
Olema Oncology initiated with a Buy at Citi
No recent press releases are available for OLMA
OLMA Financials
Key terms
Ad Feedback
OLMA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OLMA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
